A Phase 3 interventional study of CTX001 in Beta-Thalassemia, Thalassemia and Sickle Cell Disease, sponsored by Vertex Pharmaceuticals Incorporated. Enrolling by invitation at 20 sites in 6 countries. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2026-08-11.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 91 studies in beta-Thalassemia with a site in United States — 22 open to participants now, 36 under way, 8 of them phase 3. beta-Thalassemia · United States.
Among the 91 studies in beta-Thalassemia with a site in United States, this one is the 9th largest by planned enrollment of the 71 interventional ones that give a count, is one of 7 that started in 2021, is one of 12 in phase 3, reaches primary completion later than 33 of the 35 other live ones, and was the 62nd registered.
294 studies on the registry are indexed under beta-Thalassemia; 69 are open to participants now.
Browse beta-Thalassemia studies →22 of the 91 studies in beta-Thalassemia with a site in United States are open now. Recruiting first, the newest first:
Agios Pharmaceuticals, Inc. · Sites in United States
Ages 1–17
Agios Pharmaceuticals, Inc. · Sites in United States
Ages 1–17
National Heart, Lung, and Blood Institute (NHLBI) · Sites in United States
Ages 4–65
Daniel Bauer · Sites in United States
Ages 13–40
xCures · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 43 beta-Thalassemia studies recruiting now, 10 (23%) set no upper age limit and 31 (72%) stop at 75 or younger; 34 take children under 18; 6 take healthy volunteers.
This study: 2 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
91 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 41 · Phase 3 13 · Phase 4 2
First in 1995; this study’s year is marked. 7 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 160 is above the median of 40 across 208 interventional studies indexed under beta-Thalassemia.
Median enrollment 25 across the 71 interventional studies, 150 across the 17 observational. Of the 50 that completed or were terminated, 17 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
42 of 91 have an industry lead sponsor. The 10 most frequent:
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 54 (50%) have results posted.
Vertex Pharmaceuticals Incorporated has 4 studies filed under beta-Thalassemia — fewer than ten, so there is no comparison to draw.
11 of the studies in beta-Thalassemia with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05477563Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease | 2027-06-09 |
| NCT05356195Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT) | 2027-11-14 |
| NCT01962415Paul SzabolcsReduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT | 2026-11 |
| NCT03655223RTI InternationalEarly Check: Expanded Screening in Newborns | 2026-11-30 |
| NCT06421636Regeneron PharmaceuticalsA Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body | 2026-12-03 |
Add all 11 to your calendar (.ics) → With an account.
Among the 91 studies in beta-Thalassemia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multi-site, open- label rollover study to evaluate the long-term safety and efficacy of CTX001 in pediatric and adult participants who received CTX001 in parent studies 111 (NCT03655678) 141 (NCT05356195) or 161 (NCT05477563) (transfusion-dependent β-thalassemia [TDT] studies) or Study 121 (NCT03745287) or 151 (NCT05329649) or 161(NCT05477563) (severe sickle cell disease [SCD] studies).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants who complete or discontinue one of the multiple parent studies (CTX001-111, CTX001-121, CTX001-141, CTX001-151 and CTX001-161) after CTX001 infusion will be asked to participate in this long-term follow-up study.
Biological: CTX001
CTX001 infusion.
Also known as: Exagamglogene autotemcel, Exa-cel
New malignancies
Time frame: Signing of informed consent up to 15 years post CTX001 infusion
New or worsening hematologic disorders
Time frame: Signing of informed consent up to 15 years post CTX001 infusion
All-cause mortality
Time frame: Signing of informed consent up to 15 years post CTX001 infusion
Serious adverse events (SAEs)
Time frame: Signing of informed consent up to 15 years post CTX001 infusion
CTX001-related adverse events (AEs)
Time frame: Signing of informed consent up to 15 years post CTX001 infusion
TDT and SCD: Total Hemoglobin (Hb) concentration over time
Time frame: Up to 15 years post CTX001 infusion
TDT and SCD: Fetal Hemoglobin (HbF) concentration over time
Time frame: Up to 15 years post CTX001 infusion
TDT and SCD: Proportion of alleles with intended genetic modification present in peripheral blood over time
Time frame: Up to 15 years post CTX001 infusion
TDT and SCD: Proportion of alleles with intended genetic modification present in CD34+ cells of the bone marrow over time
Time frame: Up to 15 years post CTX001 infusion
TDT and SCD: Change in patient-reported outcome (PRO) over time in participants ≥18 years of age assessed using EuroQol quality of life scale (EQ-5D-5L) for participants from study 111 and 121 only
Time frame: Up to 5 years post CTX001 infusion
TDT and SCD: Change in PROs over time in participants ≥18 years of age assessed using functional assessment of cancer therapy-bone marrow transplant (FACT-BMT) questionnaire for participants from study 111, 121 and 161 only
Time frame: Up to 5 years post CTX001 infusion
TDT and SCD: Change in PROs over time in participants <18 years assessed using EQ-5D-Youth (EQ-5D-Y) from study 111,121,141 and 151 only
Time frame: Up to 5 years post CTX001 infusion
TDT and SCD: Change in PROs over time in participants <18 years assessed using pediatric quality of life inventory (PedsQL) Core
Time frame: Up to 5 years post CTX001 infusion
TDT: Proportion of participants achieving transfusion independence for at least 12 consecutive months (TI12)
Time frame: From 60 days after last RBC transfusion up to 15 years post-CTX001 infusion
TDT: Proportion of participants achieving transfusion independence for at least 6 consecutive months (TI6)
Time frame: From 60 days after last RBC transfusion up to 15 years post-CTX001 infusion
TDT: Proportion of participants achieving at least 95%, 90%, 85%, 75%, 50% reduction from baseline in annualized volume of RBC transfusions starting after month 10 after CTX001 infusion for participants who have not achieved TI12
Time frame: From Month 10 up to 15 years post-CTX001 infusion
TDT: Duration of transfusion free in participants who have achieved TI12
Time frame: From 60 days after last RBC transfusion up to 15 years post CTX001 infusion
TDT: Relative reduction from baseline in annualized volume of RBC transfusions starting after Month 10 after CTX001 infusion for participants who have not achieved TI12
Time frame: From Month 10 up to 15 years post-CTX001 infusion
TDT: Iron overload as measured by liver iron concentration (LIC), cardiac iron concentration (CIC), and ferritin for beta-Thalassemia participants
Time frame: Up to 8 years post CTX001 infusion for LIC; up to 5 years post CTX001 infusion for CIC and up to 15 years post CTX001 infusion for ferritin
TDT: Proportion of participants receiving iron removal therapy over time
Time frame: Up to 15 years post CTX001 infusion
SCD: Proportion of participants who have not experienced any severe vaso-occlusive crises (VOC) for at least 12 consecutive months (VF12)
Time frame: From 60 days after last RBC transfusion up to 15 years post-CTX001 infusion
SCD: Proportion of participants with SCD free from inpatient hospitalization for severe VOCs sustained for at least 12 months (HF12)
Time frame: From 60 days after last RBC transfusion up to 15 years post-CTX001 infusion
SCD: Proportion of participants with at least 90 percent (%), 80%, 75% or 50% reduction in annualized rate of severe VOCs
Time frame: From 60 days after last RBC transfusion up to 15 years post-CTX001 infusion
SCD: Relative change from baseline in annualized rate of severe VOCs
Time frame: From 60 days after last RBC transfusion up to 15 years post-CTX001 infusion
SCD: Duration of severe VOC free in participants who have achieved VF12
Time frame: From 60 days after last RBC transfusion up to 15 years post CTX001 infusion
SCD: Relative change from baseline in rate of inpatient hospitalizations for severe VOCs
Time frame: From 60 days after last RBC transfusion up to 15 years post-CTX001 infusion
SCD: Relative change from baseline in annualized duration of hospitalization for severe VOCs
Time frame: From 60 days after last RBC transfusion up to 15 years post-CTX001 infusion
SCD: Proportion of participants with sustained HbF ≥20% for at least 3 months
Time frame: From 60 days after last RBC transfusion up to 15 years post-CTX001 infusion
SCD: Proportion of participants with sustained HbF ≥20% for at least 6 months
Time frame: From 60 days after last RBC transfusion up to 15 years post-CTX001 infusion
SCD: Proportion of participants with sustained HbF ≥20% for at least 12 months
Time frame: From 60 days after last RBC transfusion up to 15 years post-CTX001 infusion
SCD: Change in volume of RBCs transfused for SCD-related indications over time
Time frame: Up to 15 years post CTX001 infusion
SCD: Change from baseline in reticulocytes/erythrocytes over time
Time frame: From baseline up to 15 years post CTX001 infusion
SCD: Change from baseline in lactate dehydrogenase (LDH) over time
Time frame: From baseline up to 15 years post CTX001 infusion
SCD: Change from baseline in haptoglobin over time
Time frame: From baseline up to 15 years post CTX001 infusion
SCD: Change from baseline in total bilirubin over time
Time frame: From baseline up to 15 years post CTX001 infusion
SCD: Change from baseline in indirect bilirubin over time
Time frame: From baseline up to 15 years post CTX001 infusion
SCD: Change in SCD-specific PROs over time in participants ≥18 years of age assessed using adult sickle cell quality of life measurement system (ASCQ-Me) (participants from Study 121 and 161 only)
Time frame: Up to 5 years post CTX001 infusion
SCD: Change in SCD-specific PROs over time in participants <18 years of age assessed using PedsQL Generic Core SCD module from studies 111,121,141,151 and 161
Time frame: Up to 5 years post CTX001 infusion
SCD: Change in PRO over time assessed using 11-point numerical rating scale (NRS)
Time frame: Up to 5 years post CTX001 infusion
SCD: Change in PROs over time assessed using Wong Baker FACES pain scale
Time frame: Up to 5 years post CTX001 infusion
SCD: Change in PROs over time using face, legs, activity, cry, consolability (FLACC) behavioral pain scale
Time frame: Up to 5 years post CTX001 infusion
Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/our-science/clinical-trials-data-sharing/
Started Jan 2021 (actual). Primary completion is estimated for Sep 2039, 224 months after the start.
Of 18 phase 3 interventional studies under beta-Thalassemia, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 67. This study's planned 224 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Exagamglogene autotemcel
Vertex Pharmaceuticals Incorporated →